{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T03:45:58Z","timestamp":1780717558095,"version":"3.54.1"},"reference-count":46,"publisher":"American Society of Hematology","issue":"7","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,8,16]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Clonal cytogenetic abnormalities are a major risk factor for relapse after hematopoietic cell transplantation (HCT) for myelodysplastic syndrome (MDS). We determined the impact of the recently established 5-group cytogenetic classification of MDS on outcome after HCT. Results were compared with the impact of the International Prognostic Scoring System (IPSS) 3 cytogenetic risk groups, and the additional effect of a monosomal karyotype was assessed. The study included data on 1007 patients, 1-75 years old (median 45 years), transplanted from related (n = 547) or unrelated (n = 460) donors. Various conditioning regimens were used, and marrow, peripheral blood, or cord blood served as stem cell source. Both IPSS and 5-group cytogenetic risk classifications were significantly associated with post-HCT relapse and mortality, but the 5-group classification discriminated more clearly among the lowest- and highest-risk patients. A monosomal karyotype tended to further increase the rates of relapse and mortality, even after considering the IPSS or 5-group classifications. In addition, the pathologic disease category correlated with both relapse and mortality. Mortality was also impacted by patient age, donor type, conditioning regimen, platelet count, and etiology of MDS. Although mortality declined significantly in recent years, novel strategies are needed to overcome the barrier of high-risk cytogenetics.<\/jats:p>","DOI":"10.1182\/blood-2012-04-423046","type":"journal-article","created":{"date-parts":[[2012,7,7]],"date-time":"2012-07-07T00:49:51Z","timestamp":1341622191000},"page":"1398-1408","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":135,"title":["Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS"],"prefix":"10.1182","volume":"120","author":[{"given":"H. Joachim","family":"Deeg","sequence":"first","affiliation":[{"name":"Fred Hutchinson Cancer Research Center, Seattle, WA;"},{"name":"University of Washington Medical Center\/Seattle Cancer Care Alliance, Seattle, WA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart L.","family":"Scott","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Research Center, Seattle, WA;"},{"name":"University of Washington Medical Center\/Seattle Cancer Care Alliance, Seattle, WA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Fang","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Research Center, Seattle, WA;"},{"name":"University of Washington Medical Center\/Seattle Cancer Care Alliance, Seattle, WA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard M.","family":"Shulman","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Research Center, Seattle, WA;"},{"name":"University of Washington Medical Center\/Seattle Cancer Care Alliance, Seattle, WA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boglarka","family":"Gyurkocza","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Research Center, Seattle, WA;"},{"name":"University of Washington Medical Center\/Seattle Cancer Care Alliance, Seattle, WA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Myerson","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Research Center, Seattle, WA;"},{"name":"University of Washington Medical Center\/Seattle Cancer Care Alliance, Seattle, WA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Pagel","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Research Center, Seattle, WA;"},{"name":"University of Washington Medical Center\/Seattle Cancer Care Alliance, Seattle, WA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Platzbecker","sequence":"additional","affiliation":[{"name":"Universitaetsklinikum Carl Gustav Carus, Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aravind","family":"Ramakrishnan","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Research Center, Seattle, WA;"},{"name":"University of Washington Medical Center\/Seattle Cancer Care Alliance, Seattle, WA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerald P.","family":"Radich","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Research Center, Seattle, WA;"},{"name":"University of Washington Medical Center\/Seattle Cancer Care Alliance, Seattle, WA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda M.","family":"Sandmaier","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Research Center, Seattle, WA;"},{"name":"University of Washington Medical Center\/Seattle Cancer Care Alliance, Seattle, WA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Sorror","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Research Center, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek L.","family":"Stirewalt","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Research Center, Seattle, WA;"},{"name":"University of Washington Medical Center\/Seattle Cancer Care Alliance, Seattle, WA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy A.","family":"Wilson","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Research Center, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer","family":"Storb","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Research Center, Seattle, WA;"},{"name":"University of Washington Medical Center\/Seattle Cancer Care Alliance, Seattle, WA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick R.","family":"Appelbaum","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Research Center, Seattle, WA;"},{"name":"University of Washington Medical Center\/Seattle Cancer Care Alliance, Seattle, WA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ted","family":"Gooley","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Research Center, Seattle, WA;"},{"name":"University of Washington Medical Center\/Seattle Cancer Care Alliance, Seattle, WA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"16","key":"2019111808554539800_B1","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1200\/JCO.2010.31.3353","article-title":"Association of comorbidities with overall survival in myelodysplastic syndrome: development of a prognostic model.","volume":"29","author":"Naqvi","year":"2011","journal-title":"J Clin Oncol"},{"issue":"6","key":"2019111808554539800_B2","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","article-title":"International scoring system for evaluating prognosis in myelodysplastic syndromes [erratum appears in Blood. 1998;91(3):1100].","volume":"89","author":"Greenberg","year":"1997","journal-title":"Blood"},{"issue":"11","key":"2019111808554539800_B3","doi-asserted-by":"crossref","first-page":"232a","DOI":"10.1182\/blood.V106.11.788.788","article-title":"A WHO classification-based prognostic scoring system (WPSS) for predicting survival in myelodysplastic syndromes [abstract].","volume":"106","author":"Malcovati","year":"2005","journal-title":"Blood"},{"issue":"23","key":"2019111808554539800_B4","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1200\/JCO.2006.08.5696","article-title":"Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes.","volume":"25","author":"Malcovati","year":"2007","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111808554539800_B5","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1182\/blood-2008-03-143735","article-title":"WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO).","volume":"112","author":"Alessandrino","year":"2008","journal-title":"Blood"},{"issue":"4","key":"2019111808554539800_B6","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1182\/blood-2002-02-0527","article-title":"Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome.","volume":"100","author":"Deeg","year":"2002","journal-title":"Blood"},{"issue":"2","key":"2019111808554539800_B7","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.bbmt.2008.11.015","article-title":"IPSS poor-risk karyotype as a predictor of outcome for patients with myelodysplastic syndrome following myeloablative stem cell transplantation.","volume":"15","author":"Nevill","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"2019111808554539800_B8","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.bbmt.2007.01.079","article-title":"Impact of cytogenetics on outcome of de novo and therapy-related AML and MDS after allogeneic transplantation.","volume":"13","author":"Armand","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"2019111808554539800_B9","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1200\/JCO.2011.35.6394","article-title":"New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge.","volume":"30","author":"Schanz","year":"2012","journal-title":"J Clin Oncol"},{"issue":"15","key":"2019111808554539800_B10","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1200\/JCO.2010.28.3978","article-title":"Coalesced multicentric analysis of 2351 patients with myelodysplastic syndromes indicates an underestimation of poor-risk cytogenetics of myelodysplastic syndromes in the international prognostic scoring system.","volume":"29","author":"Schanz","year":"2011","journal-title":"J Clin Oncol"},{"issue":"29","key":"2019111808554539800_B11","doi-asserted-by":"crossref","first-page":"4791","DOI":"10.1200\/JCO.2008.16.0259","article-title":"Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype.","volume":"26","author":"Breems","year":"2008","journal-title":"J Clin Oncol"},{"issue":"13","key":"2019111808554539800_B12","doi-asserted-by":"crossref","first-page":"4608","DOI":"10.1182\/blood-2007-06-096966","article-title":"Hematopoietic cell transplantation-specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences.","volume":"110","author":"Sorror","year":"2007","journal-title":"Blood"},{"key":"2019111808554539800_B13","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1399-0039.2006.759_2.x","article-title":"Clinical significance of donor-recipient HLA matching on survival after myeloablative hematopoietic cell transplantation from unrelated donors.","volume":"69","author":"Petersdorf","year":"2007","journal-title":"Tissue Antigens"},{"issue":"12","key":"2019111808554539800_B14","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","article-title":"Defining the intensity of conditioning regimens: working definitions.","volume":"15","author":"Bacigalupo","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"2019111808554539800_B15","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O","article-title":"Estimation of failure probabilities in the presence of competing risks: new representations of old estimators.","volume":"18","author":"Gooley","year":"1999","journal-title":"Stat Med"},{"issue":"3","key":"2019111808554539800_B16","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1053\/bbmt.2002.v8.pm11939606","article-title":"Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome after conditioning with busulfan and fractionated total body irradiation is associated with low relapse rate but considerable nonrelapse mortality.","volume":"8","author":"Jurado","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"issue":"27","key":"2019111808554539800_B17","doi-asserted-by":"crossref","first-page":"4246","DOI":"10.1200\/JCO.2006.09.7865","article-title":"Comorbidity and disease status-based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation.","volume":"25","author":"Sorror","year":"2007","journal-title":"J Clin Oncol"},{"issue":"5","key":"2019111808554539800_B18","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/bmt.2009.253","article-title":"Multicenter validation study of a transplantation-specific cytogenetics grouping scheme for patients with myelodysplastic syndromes.","volume":"45","author":"Armand","year":"2010","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"2019111808554539800_B19","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1182\/blood-2011-10-385781","article-title":"Prognostic value of monosomal karyotype in comparison to complex aberrant karyotype in acute myeloid leukemia: a study on 824 cases with aberrant karyotype.","volume":"119","author":"Haferlach","year":"2012","journal-title":"Blood"},{"issue":"21","key":"2019111808554539800_B20","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1182\/blood.V118.21.2028.2028","article-title":"Prognostic impact of a monosomal karyotype on the outcome of patients with acute myeloid leukemia or myelodysplastic syndrome undergoing allogeneic stem cell transplantation [abstract].","volume":"118","author":"Hemmati","year":"2011","journal-title":"Blood"},{"issue":"21","key":"2019111808554539800_B21","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1182\/blood.V118.21.158.158","article-title":"The influence of monosomal karyotype on survival in patients with acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation: a retrospective survey on behalf of the acute leukemia working party of the European Group for Blood and Marrow Transplantation (EBMT) [abstract].","volume":"118","author":"Brands-Nijenhuis","year":"2011","journal-title":"Blood"},{"issue":"21","key":"2019111808554539800_B22","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1182\/blood.V118.21.1724.1724","article-title":"Prognostic impact of monosomal karyotype in patients with myelodysplastic syndrome and abnormal karyotype: a report from the Spanish Group of MDS (GESMD) [abstract].","volume":"118","author":"Valc\u00e1rcel","year":"2011","journal-title":"Blood"},{"issue":"5","key":"2019111808554539800_B23","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1200\/JCO.2000.18.5.963","article-title":"Allogeneic bone marrow transplantation for therapy-related myelodsyplastic syndrome and acute myeloid leukemia: a long-term study of 70 patients. Report of the French Society of bone marrow transplantation.","volume":"18","author":"Yakoub-Agha","year":"2000","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019111808554539800_B24","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1182\/blood-2002-11-3615","article-title":"Treosulfan and fludarabine: a new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation.","volume":"103","author":"Casper","year":"2004","journal-title":"Blood"},{"issue":"3","key":"2019111808554539800_B25","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/sj.leu.2403640","article-title":"Value of chemotherapy before allogeneic hematopoietic stem cell transplantation from an HLA-identical sibling donor for myelodysplastic syndrome.","volume":"19","author":"Nakai","year":"2005","journal-title":"Leukemia"},{"issue":"24","key":"2019111808554539800_B26","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1200\/JCO.2011.35.8135","article-title":"Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure.","volume":"29","author":"Pr\u00e9bet","year":"2011","journal-title":"J Clin Oncol"},{"key":"2019111808554539800_B27","article-title":"Pre-transplant therapy with azacitidine verus induction chemotherapy and post-transplant outcome in patients with MDS","author":"Gerds","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"2019111808554539800_B28","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.bbmt.2004.10.001","article-title":"Pretransplantation induction chemotherapy and posttransplantation relapse in patients with advanced myelodysplastic syndrome.","volume":"11","author":"Scott","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"2019111808554539800_B29","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1182\/blood-2007-02-076307","article-title":"Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic disorders.","volume":"110","author":"Chang","year":"2007","journal-title":"Blood"},{"issue":"9","key":"2019111808554539800_B30","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1182\/blood-2009-10-249128","article-title":"Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia.","volume":"115","author":"Litzow","year":"2010","journal-title":"Blood"},{"issue":"17","key":"2019111808554539800_B31","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1001\/jama.2011.1558","article-title":"Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies.","volume":"306","author":"Sorror","year":"2011","journal-title":"JAMA"},{"issue":"3","key":"2019111808554539800_B32","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1200\/JCO.2009.21.8073","article-title":"Allogeneic hematopoietic stem-cell transplantation for patients 50 years or older with myelodysplastic syndromes or secondary acute myeloid leukemia.","volume":"28","author":"Lim","year":"2010","journal-title":"J Clin Oncol"},{"issue":"11","key":"2019111808554539800_B33","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1200\/JCO.2009.25.4821","article-title":"Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome.","volume":"28","author":"McClune","year":"2010","journal-title":"J Clin Oncol"},{"issue":"22","key":"2019111808554539800_B34","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1004383","article-title":"Reduced mortality after allogeneic hematopoietic-cell transplantation.","volume":"363","author":"Gooley","year":"2010","journal-title":"N Engl J Med"},{"issue":"10","key":"2019111808554539800_B35","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.bbmt.2009.06.019","article-title":"Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective [erratum appears in Biol Blood Marrow Transplant. 2010;16(2):294].","volume":"15","author":"Tomblyn","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"2019111808554539800_B36","first-page":"212","article-title":"5Azacytidine prior to allogeneic transplantation effectively reduces relapse, TRM and overall mortality in high-risk myelodysplastic and secondary AML [abstract].","volume":"41","author":"McCarthy","year":"2008","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"2019111808554539800_B37","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.1182\/blood.V89.8.3055","article-title":"Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation.","volume":"89","author":"Slattery","year":"1997","journal-title":"Blood"},{"issue":"3","key":"2019111808554539800_B38","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.bbmt.2010.05.007","article-title":"Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies.","volume":"17","author":"Nemecek","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"issue":"27","key":"2019111808554539800_B39","doi-asserted-by":"crossref","first-page":"5444","DOI":"10.1182\/blood-2009-03-213298","article-title":"Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome.","volume":"114","author":"Pagel","year":"2009","journal-title":"Blood"},{"issue":"5","key":"2019111808554539800_B40","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.bbmt.2005.12.036","article-title":"Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan\/cyclophosphamide regimen.","volume":"12","author":"Deeg","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"issue":"26","key":"2019111808554539800_B41","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1056\/NEJMoa1013343","article-title":"Clinical effect of point mutations in myelodysplastic syndromes.","volume":"364","author":"Bejar","year":"2011","journal-title":"N Engl J Med"},{"issue":"5","key":"2019111808554539800_B42","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1053\/j.seminoncol.2011.04.007","article-title":"Classification and prognostic evaluation of myelodysplastic syndromes [review].","volume":"38","author":"Cazzola","year":"2011","journal-title":"Semin Oncol"},{"issue":"10","key":"2019111808554539800_B43","doi-asserted-by":"crossref","first-page":"4586","DOI":"10.1182\/blood-2006-10-054924","article-title":"Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation.","volume":"109","author":"Armand","year":"2007","journal-title":"Blood"},{"issue":"5","key":"2019111808554539800_B44","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1200\/JCO.2010.31.1175","article-title":"Unraveling the molecular pathophysiology of myelodysplastic syndromes [review].","volume":"29","author":"Bejar","year":"2011","journal-title":"J Clin Oncol"},{"issue":"8","key":"2019111808554539800_B45","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1073\/pnas.0712391105","article-title":"Dysregulation of IL-32 in myelodysplastic syndrome and chronic myelomonocytic leukemia modulates apoptosis and impairs NK function.","volume":"105","author":"Marcondes","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"15","key":"2019111808554539800_B46","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1056\/NEJMoa1103283","article-title":"Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts.","volume":"365","author":"Papaemmanuil","year":"2011","journal-title":"N Engl J Med"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/120\/7\/1398\/1499036\/zh803312001398.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/120\/7\/1398\/1499036\/zh803312001398.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,10]],"date-time":"2020-07-10T11:00:23Z","timestamp":1594378823000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/120\/7\/1398\/30757\/Fivegroup-cytogenetic-risk-classification"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8,16]]},"references-count":46,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2012,8,16]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2012-04-423046","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,8,16]]}}}